An alkylating agent of value against both hematologic malignancies and solid tumors.
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.